The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
ApexOnco Front Page
Recent articles
Tecvayli and Hernexeos might get speedy approval decisions.
The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
The company adds royalty aggregation to its R&D business.
And AbbVie and Genmab scoop their ASH presentation with new data.
But Enhertu is coming.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
The restructured biotech’s new lead project enters phase 1.
